Raymond James Starts Mirum Pharamceuticals (MIRM) at Outperform

Raymond James analyst Steven Seedhouse initiates coverage on Mirum Pharamceuticals (NASDAQ: MIRM) with an Outperform rating and a price target of $28.00.

• "Despite mixed results in previous maralixibat (ASBT inhibitor) trials in rare pediatric and adult liver diseases, and the circuitous route to get here (Lumena -> Shire -> Mirum), the most recent datasets for maralixibat in Alagille Syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) suggest maralixibat is effective at reducing bile acids and pruritus (key endpoints in cholestatic liver diseases) and was simply underdosed in prior studies."

For an analyst ratings summary and ratings history on Mirum Pharamceuticals click here. For more ratings news on Mirum Pharamceuticals click here.

Shares of Mirum Pharamceuticals closed at $14.77 yesterday.

You May Also Be Interested In

• Canaccord Genuity Starts TMX Group Ltd (X:CN) (TMXXF) at Buy
• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Amazon.com (AMZN) PT Raised to $215 at UBS